Vitamin C will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations
Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls Hospital length stay will also be compared between the two groups

Start Date19 Feb 2025

Sponsor / Collaborator

Cairo University

NCT06710899

/ Not yet recruitingEarly Phase 1

Does Vitamin C Improve the Efficacy of Methenamine Hippurate (Hiprex®) in Prophylaxis of Recurrent Urinary Tract Infections? A Proof of Concept Study

A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women

Start Date01 Jan 2025

Sponsor / Collaborator

University Hospitals of North Midlands NHS Trust

CTRI/2024/07/070297

/ Not yet recruitingPhase 3IIT

Evaluation of gingival depigmentation using microneedling procedure with vitamin-c and electrosurgery: A split mouth randomized controlled trial. - NIL

Start Date01 Jan 2025

Sponsor / Collaborator-

100 Clinical Results associated with Ascorbic Acid

100 Translational Medicine associated with Ascorbic Acid

100 Patents (Medical) associated with Ascorbic Acid

192,956

Literatures (Medical) associated with Ascorbic Acid

01 Jun 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Strong enhancement on diclofenac degradation in Cu(II)/H2O2 system by adding ascorbic acid: Efficiency, mechanism and influencing factors

Author: Zou, Jing ; Li, Fei ; Yang, Zhimin ; Chen, Lingxin ; Qiu, Shiyi ; Wu, Jianying ; Zhou, Zhenming ; Liu, Shupo ; Cai, Yajuan

Utilization of trace Cu(II) (at μM level) inherently existing in wastewater to activate hydrogen peroxide (H2O2) has exhibited significant potential to remove aqueous organic contaminants.Nevertheless, the Cu(II)/H2O2 system was only efficient under alk. conditions.Herein, ascorbic acid (H2A), an environmentally benign and natural reductant, was introduced to broaden pH range of Cu(II)/H2O2 process by expediting the Cu(II)/Cu(I) cycle.The H2A/Cu(II)/H2O2 system performed well in degrading diclofenac across a wide pH range from 4.0 to 9.0, and its kinetic rate constant of diclofenac elimination was 247 times greater than its counterpart without H2A at the optimal pH of 6.0, outperforming the performance of most previously reported reductant-enhanced Cu(II)/H2O2 system.ESR anal., periodate colorimetric method, and in situ Raman spectroscopy tests indicated that hydroxyl radical (HO.), rather than Cu(III), was the dominant reactive species of diclofenac degradationThirteen degradation products of diclofenac were identified by LC-Q-TOF-MS, and five different elimination pathways were proposed.Furthermore, the presence of SO2-4 exerted an insignificant influence on diclofenac degradation, while the addition of Cl-, HCO-3 and humic acid slightly suppressed the abatement of diclofenac.H2A/Cu(II)/H2O2 system was still highly efficient in degrading diclofenac in actual water matrix (i.e., reservoir water and lake water).Overall, this study provided an eco-friendly approach to enhance the oxidation capacity of the Cu(II)/H2O2 system over a wide pH range, which might be a potential technol. for degrading refractory organic pollutants in water treatment.

01 Jun 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Recovery of all-solid-state sodium-ion batteries cathode and solid electrolyte using deep eutectic solvents as green solvents

Author: Wang, Yanlong ; Wang, Chenyang ; Zhang, Qing ; Zhang, Ziyang ; Shi, Zhuojia ; Shen, Yaxue ; Chen, Yu ; Feng, Minghui

All-solid-state sodium-ion batteries (ASIBs) have wide application prospects in the fields of renewable energy and elec. vehicles due to their high energy d. and long-life cycle.With the rapid development of industrialization, the number of ASIBs will increase, which might result in a significant increase in the price of metal in ASIBs in the near future.Many waste ASIBs would be produced and lead to waste of resources, environmental pollution and health hazards.Therefore, it is of vital important significance to provide a green and efficient method to recover waste ASIBs.Here, we for the first time propose a mild, green and low-cost strategy for recovery of cathode materials and all-solid-state electrolyte from spent ASIBs by using deep eutectic solvents (DESs).Results show that the highest leaching efficiency of Na in ASIBs cathode materials and all-solid-state electrolytes by using DESs is 88.3% and 56.9%, resp.Moreover, we use a simple anti-solvent approach of recovering the metals in the leachate with low cost at room temperatureThis work would provide a mild, green and low-cost strategy from recycling metals in cathode materials and all-solid-state electrolyte from waste ASIBs.

01 May 2025·TALANTA

Antifouling ONOO− electrochemical sensor based on copper–platinum bimetallic nanoparticle–modified N-doped biomass porous carbon fibres composites

Article

Author: Li, Lin ; Yan, Liqiang ; Zhang, Jie ; Gu, Chen ; Wu, Xiongzhi ; Li, Ying ; Zhou, Jianmei

Monitoring reactive nitrogen species (RNS) in complex biological media is essential for evaluating the health status of living organisms; however, biofouling on the sensor surface restricts its applications. To overcome this issue, we developed an antifouling electrochemical sensing platform using copper-platinum bimetallic nanoparticles/N-doped biomass porous carbon fibres (Cu-PtNPs/N-BCF) for directly detecting peroxynitrite anion (ONOO^-), a major type of RNS. Cyclic voltammetry measurements demonstrated that the Cu-PtNPs/N-BCF-2 nanocomposite, synthesised at a molar ratio of 1:1 between Co²⁺ and Zn²⁺, exhibited exceptional electrocatalytic activity for ONOO^- oxidation. The sensor exhibited a wide linear range (2.970 × 10^-5 - 63.80 μM) and a low detection limit (9.900 × 10^-3 nM) (S/N = 3). Notably, following a series of control tests, the Cu-PtNPs/N-BCF-2/GCE exhibited superior surface hydrophilicity and enhanced biofouling resistance compared with bare GCE. In addition, the developed sensor demonstrated strong sensitivity for ONOO^- detection in serum containing Bovine Serum Albumin. Furthermore, an electrochemical strategy was used to confirm the protective effect of ascorbic acid by simulating a complex biological media environment with serum. The sensor successfully detected ONOO^- in serum samples. This study aims to present a promising approach for effectively evaluating active molecules in complex biological systems.

News (Medical) associated with Ascorbic Acid

28 Jan 2025

·www.prnewswire.com

Debut Unveils AI-powered Ingredient Discovery Platform to Fuel Biotech Innovation for All Beauty Brands Globally through Partner KDC/one

New discovery engine, BeautyORB™ by Debut, will create two novel, peak-performing biotech ingredients each year, giving beauty brands access to game-changing clinical claims and product innovation. Debut's new partnership with contract manufacturer KDC/one enables brands of all sizes to harness the power of biotech. SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Debut, the biotech beauty leader, announced today the launch of BeautyORB™, an AI-powered innovation engine that provides a new way to discover novel ingredients for best-in-class claims for beauty brands, from a typical time horizon of several years to two Debut ingredients launched each year. The genomics-based AI platform, which is on par with pharmaceutical-grade technology, has already fueled the creation of groundbreaking ingredients addressing inflammaging, epidermal barrier repair and longevity, with brightening, anti-aging and scalp care ingredients already in the pipeline. Continue Reading Image Credit: Billy Economou, BE Studios "With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction. This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims," said Joshua Britton, Ph.D, Founder and CEO of Debut. "We don't have to rely on an array of existing ingredients to test against specific claims, and we don't have to go into the field to find rare ingredients in plants. All this can be done at the click of a button, cutting out years from the innovation cycle and accessing ingredients that no one has seen before. We can turn on and off molecular pathways differently and use AI to discover what molecules can affect those pathways. The result is a rich, proven and growing pipeline of novel ingredients with the strongest clinical results for our customers, allowing brands to win on product performance rather than marketing". BeautyORB™ discovers new ingredients by screening 50 billion molecules for their ability to turn on cellular pathways within skin, a process that has never previously been possible in beauty. Debut's AI platform has already identified three novel, patented ingredients that achieve the highest beauty standards including scientifically-proven, clinically-tested and 100% bio-based ingredients that beat existing benchmarks. These ingredients include: DermCeutical InflammagePRO™: Best-in-class for inflammaging. Decreases inflammatory markers, supports the skin barrier and enhances elasticity. 15X better than niacinamide. DermCeutical Barrier RepairPRO™: Best-in-class for epidermal barrier repair. Defends the skin against damage from environmental aggressors. 30% better than vitamin C for skin damage repair. DermCeutical LongevityPRO™: Best-in-class for cellular longevity. Decreases markers of cellular senescence and helps maintain healthy skin cells. 2X better than vitamin C for skin health. "With BeautyORB™, we can develop ingredients that have the targeted responses we seek, using the same technology to find ingredients that fight disease. Our tool is another key step in the convergence of pharma and beauty. We are thrilled to partner with the industry leading contract manufacturer KDC/one to create finished products of the highest quality, in tandem with Debut's custom formulation business, BiotechXBeautyLabs™, to achieve our mission of reinventing product performance with the safest sustainability credentials. Our KDC/one partnership sets the stage for a global biomanufacturing revolution in beauty," said Britton. BeautyORB™ is the latest tool to emerge from Debut's ongoing commitment to lead the beauty industry's shift to biotech, creating a community of future-forward brands and product innovators that solve existing and emerging consumer needs. Using generative AI, BeautyORB™ delivers: More than 50 billion molecule possibilities 30,000 genes tested per molecule using omics technology 25,000 genes tested per second 21,000 molecules screened in silico per second for deep learning 200+ new biological pathways tested per molecule Over 60 million data points, with 100 million over the next 12 months About Debut The leader in biotech beauty Debut is pioneering the beauty industry's shift from traditionally sourced ingredients derived from petroleum and cultivation to high-performing and inherently sustainable biotech ingredients. As a fully vertically-integrated global company, Debut creates superior, scientifically-engineered, bio-based and clinically-proven products and brands at scale to benefit people and planet. Our mission is to create a new beauty standard based on potency, purity, and performance. About KDC/one Industry leading Contract Manufacturer KDC/one's Beauty & Personal Care manufacturing platform includes state-of-the-art facilities across North America, Europe, and Asia, allowing us to seamlessly deliver solutions for the complex production requirements of our global customers. With a global network of manufacturing, R&D, innovation hubs, and showrooms, KDC/one has end-to-end capabilities across formulation, design, packaging, and manufacturing to service a wide range of customer types, from start-up brands to multinational consumer companies. SOURCE Debut Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

26 Dec 2024

·www.prnewswire.com

Researchers from Korea University Explore How Ascorbic acid and FGF4 Revolutionize Regenerative Medicine

Korean scientists discover a groundbreaking method to transform ordinary fibroblasts into mature cardiomyocytes SEOUL, South Korea, Dec. 26, 2024 /PRNewswire/ -- Researchers at Korea University have achieved a significant breakthrough in regenerative medicine. They have demonstrated how fibroblast growth factor 4 and Ascorbic acid, known as vitamin C, can induce the trans-differentiation of fibroblasts into functional cardiomyocytes. This discovery activates key cellular pathways and offers hope for developing treatments for cardiovascular diseases, the leading cause of death worldwide. Continue Reading This diagram illustrates how the combination of fibroblast growth factor 4 and ascorbic acid activates the JAK2-STAT3 signaling pathway, promoting the maturation of induced cardiomyocytes (iCMs). This approach effectively reprograms fibroblasts into cardiomyocytes with improved structure and function, offering exciting possibilities for regenerative medicine. Cardiovascular disease continues to lead as the primary cause of death across the globe, taking millions of lives every year. Damage caused by these diseases is particularly difficult to repair, since the heart has minimal ability to regenerate itself. But what if we could reprogram the body's own cells to restore damaged tissue? This groundbreaking question has been tackled by scientists at Korea University, led by Dr. Myeong-Hwa Song. The team has unveiled an innovative technique to convert fibroblasts—common connective tissue cells—into mature and functional induced cardiomyocytes (iCMs). Their method relies on combining fibroblast growth factor 4 (FGF4) with vitamin C, a pairing that accelerates cell maturation and enhances function. "Our findings bring us closer to transforming regenerative medicine into practical therapies," says Dr. Song, who is based at Korea University's Department of Cardiology and in Seoul, South Korea. "This research takes an important step toward using a patient's own cells to repair their heart." Direct cardiac reprogramming, a process that bypasses the intermediate stem cell stage, allows fibroblasts to be converted into iCMs. While this approach holds significant promise, scientists have struggled to produce mature and fully functional cardiomyocytes. The Korea University team addressed this hurdle by activating a critical cellular mechanism: the JAK2–STAT3 signaling pathway. Through their research, the scientists employed advanced techniques like RNA sequencing, fluorescence imaging, and electrophysiological testing. Their results revealed key improvements: better cell structure with well-defined sarcomeres and T-tubules, enhanced electrical activity with improved ion channel function, and a higher efficiency in generating mature, fully reprogrammed cardiomyocytes. Dr. Song explained that the JAK2-STAT3 pathway was crucial to these outcomes, enabling the induction of cells that closely mimic the structure and function of natural cardiomyocytes. This discovery, published in Experimental & Molecular Medicine on October 10, 2024, holds tremendous promise for regenerative medicine. By promoting mature cardiomyocytes from a patient's own tissue, it may one day be possible to repair damage from heart attacks or other cardiovascular conditions. Such an approach could reduce reliance on heart transplants and potentially revolutionize treatments for millions of patients. However, further studies are necessary to ensure this method is both safe and effective for clinical use. "We're thrilled with these results, but this is just the beginning," says Prof. Song. "More research will be required before we can bring this approach to patients. That said, the possibilities are incredibly exciting." If translated into therapy, this technique could provide a personalized solution for regenerating heart tissue, establishing a significant advance in combating cardiovascular disease. Reference Title of original paper: FGF4 and ascorbic acid enhance the maturation of induced cardiomyocytes by activating JAK2–STAT3 signaling Journal: Experimental & Molecular Medicine DOI: About Korea University College of Medicine Website: Contact: Yoo-Jung Lee +82 2 2286-1131 [email protected] SOURCE Korea University College of Medicine WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Cell Therapy

11 Dec 2024

·www.prnewswire.com

Elume Offers Fuss-Free Skincare Solutions for All Skin Tones

The Indian Skincare Brand Is Empowering Women Around the World With Simple, Pleasant, Effective Skincare Solutions FORT LAUDERDALE, Fla., Dec. 11, 2024 /PRNewswire/ -- Elume is a forward-thinking skincare company that is empowering women through simple, streamlined, and effective skincare solutions for all skin tones. The breakout Indian brand's inclusive emphasis comes from its focus on its Asian-first philosophy and its desire to meet the unique needs of the Asian consumer. Elume has created its popular and diverse skincare range through a combination of simple choices and thorough education. The company focuses on reducing overwhelm through easily accessible information and positive experiences. "Our goal is to create pleasant, fuss-free experiences for everyone, no matter their skin tone or skincare needs," said Elume co-founder Pavneet. "Élume is more than a skincare brand; it's a celebration of diversity and natural beauty. Our products, enriched with potent ingredients like Vitamin C and Niacinamide, are crafted to meet the unique needs of people with melanated skin, ensuring they receive the care and nourishment their skin deserves." As a way to make the skincare journey easier, Elume has put a heavy emphasis on transparency throughout its business activity. Formulas are easy to find and presented in concise yet comprehensive formats. This makes it easier for customers to make the best choice based on their unique skin needs. In addition, the company has an entire page devoted to ingredient descriptions to further promote education and wise purchase decisions. There is also a clear dual focus on prevention and treatment. Some products help maintain healthy skin, while others address specific concerns and conditions. One of the best examples of Elume's comprehensive and effective approach to global skincare is its Vitamin C+ range. The popular product line includes a cleanser, toner, serum, and moisturizer, all with clear descriptions and applications. The collection is celebrated for brightening and revitalizing the skin and the ability to consistently deliver exceptional results based on clearly communicated expectations. The brand has similar products formulated for skin radiance, acne, hyperpigmentation, and aging skin. Elume is more than a skincare brand. On the surface, its products offer a proactive approach to skincare, ensuring long-term skin wellness and vitality. But it goes further. The company is also committed to exceptional service as it cares for consumers and gives them the confidence to care for their bodies without the need to cover up or alter them. About Elume Elume is a brand from Skin Habits Pvt. Ltd. and was launched in 2021 in the heart of North India, Chandigarh. The company operates with family values and an emphasis on a better tomorrow. This primarily focuses on leaving behind old, harmful ideologies that have resonated for generations. The Elume team has over 20 years of expertise in skincare and embraces an Asian-first philosophy founded on meticulous research in the areas of melanated skin, tropical weather, and a fast-paced lifestyle. Its products are dermatologically tested, PETA-approved cruelty-free, and manufactured at a WHO GMP-certified factory. Learn more at elume.in. Arvin Mondal Director, International Business Development M: +91 991 590 0348 E: [email protected] SOURCE Elume WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Ascorbic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D00018	Ascorbic Acid	G01AD03 S01XA15	DB00126

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Avitaminosis	JP	NISSIN Pharmaceutical Co., Ltd.	15 May 1990
Ascorbic Acid Deficiency	JP	neo CritiCare Phama Co., Ltd.	09 Sep 1985
Iron Overload	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Methemoglobinemia	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Scurvy	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nutritional and Metabolic Diseases	Phase 3	US	Beth Israel Deaconess Medical Center, Inc.	09 Feb 2018
Shock, Septic	Phase 3	US	Beth Israel Deaconess Medical Center, Inc.	09 Feb 2018
Feeding and Eating Disorders	Phase 3	BR	EMS SA (Brazil)	01 Oct 2011
Gingivitis	Phase 3	JP	Lion Corp.	01 Sep 2006
Adenocarcinoma	Phase 2	US	McGuff Pharmaceuticals, Inc.	28 Nov 2018
Metastatic Pancreatic Cancer	Phase 2	US	McGuff Pharmaceuticals, Inc.	28 Nov 2018
Acute Myeloid Leukemia	Phase 2	US	The Case Comprehensive Cancer Center	16 Mar 2018
Myelodysplastic Syndromes	Phase 2	US	The Case Comprehensive Cancer Center	16 Mar 2018
Myeloproliferative Disorders	Phase 2	US	The Case Comprehensive Cancer Center	16 Mar 2018
Adenocarcinoma of large intestine	Phase 2	US	Weill Medical College of Cornell University	29 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Chronic Myelomonocytic Leukemia	-	High dose ascorbate	xzqpbdaccx(gmesfhliid) = increased total 5hmC levels xeavprzmap (uiruizjuts ) View more	-	07 Dec 2024
ESMO_ASIA2024	Not Applicable	Mucositis	60	Vitamin C and Zinc injections	hswbtrsfvi(tgnxbfwjff) = sksutnuqrj omjztvcbtj (lqmhewxgfm ) View more	Positive	07 Dec 2024
				vitamin C (Standard care)	hswbtrsfvi(tgnxbfwjff) = sgoqimjxud omjztvcbtj (lqmhewxgfm ) View more
NCT02905578 (Pubmed \| Redox Biol)	Phase 2	Metastatic Pancreatic Cancer	-	Gemcitabine and nab-paclitaxel only	dtfvmbvlnr(uvgucrcvdz) = apjhetxcjz ujbumvxhfu (jqqsqrowlw ) View more	-	01 Nov 2024
				Gemcitabine and nab-paclitaxel + Pharmacological ascorbate (P-AscH<sup>-</sup>)	dtfvmbvlnr(uvgucrcvdz) = pbsxtbziwn ujbumvxhfu (jqqsqrowlw ) View more
UEGW2024	Not Applicable	Intestinal preparation	540	Elobixibat plus sodium picosulfate with magnesium citrate	afncmlnmxk(gogsmihvhj): difference = -1.5 (95% CI, -4.8 to 1.6) View more	Positive	13 Oct 2024
				Split-dose 2-L polyethylene glycol with ascorbic acid
NCT04291508 (ASTER, CTgov)	Phase 2	Respiratory Failure \| Critical Illness \| Sepsis ... View more	488	Intravenous Acetaminophen (room temperature) (IV Acetaminophen-Active)	drnljdhuqe(bdiwonzyxi) = uyisjbbxms jrykgyzqwr (eiibgpzssb, qrdemvmhmt - tvbtovxjph) View more	-	27 Sep 2024
				Intravenous Vitamin C (refrigerated) (IV Vitamin C-Active)	drnljdhuqe(bdiwonzyxi) = wznqednxkw jrykgyzqwr (eiibgpzssb, hzvvgivuxe - shaxlhenft) View more
EULAR2024	Not Applicable	Tendinopathy	72	Dietary supplement (chondroitin sulfate, type I collagen, vitamin C, manganese) + corticosteroid injection	ivqxzncxih(xkvjsaiabf) = 100% in the diacerein group and 0% in the study group qiioiouhcu (edsbzlaktv ) View more	Positive	05 Jun 2024
				Diacerein + corticosteroid injection
ATS2024	Not Applicable	Sepsis \| Shock, Septic	-	Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy	iuqweckvli(iiwjxfabow) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC jtxueyreuu (hqmmollpve ) View more	-	19 May 2024
NCT04344184 (CTgov)	Phase 2	Kidney Diseases \| Acute Lung Injury \| COVID-19	47	L-ascorbic acid (Infusion)	micffunbpm(vbvxgfqxtr) = wmzgcyeghj ejcotogpaw (sjlvsqjdbp, tycccxdjge - scpykyyydo) View more	-	04 Apr 2024
				Placebo (Placebo)	micffunbpm(vbvxgfqxtr) = euxxdsojta ejcotogpaw (sjlvsqjdbp, wsyaqtqmrq - zdgraldldy) View more
NCT03433781 (CTgov)	Phase 1/2	Myelodysplastic Syndromes	4	vitamin C (Vitamin C 50 g)	jvvavjjdrl(ryjvgaeyez) = iaddwsszpt jxqfobvifi (tcnftjpoew, oirrrchqhj - gnhvzfhkui) View more	-	27 Mar 2024
				vitamin C (Vitamin C 75 g)	jvvavjjdrl(ryjvgaeyez) = xisoipszqh jxqfobvifi (tcnftjpoew, ylclbapqpw - sxbzgvxlvx) View more
NCT04046094 (CTgov)	Phase 1/2	Bladder Cancer	12	Ascorbic Acid	xxldkkbeth(xhhrcfmssm) = tinvapibcs mlowxowauv (jtclsxdnfp, gznakmoqhc - imrfhwtocw) View more	-	04 Mar 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ascorbic Acid

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation